Seeking Alpha

Alan Robert Ross'  Instablog

Alan Robert Ross
Send Message
I started investing while getting my Ph.D. at McGill University. My research was on behavioral correlates of neurological control of cardiovascular function. After 25 years as a Professor, I quit to do something more exciting and more difficult: live off of my investments. For quite some time, I... More
My company:
Trust Intelligence
My blog:
Trust Intelligence
  • One Small Step For Provectus, One Giant Step Towards Beating Cancer 2 comments
    May 13, 2014 7:30 PM | about stocks: PVCT

    This is a momentous day for Provectus and a significant step forward for those cancer patients and their families who will be helped by PV-10. It is a tribute to the vision, determination and hard work of Management.

    And it really is only the beginning.

    There are celebrations in many quarters tonight and I hope all the shareholders, determined to be invested through the endgame, feel renewed conviction tonight.

    *******************************

    Provectus Biopharmaceuticals Inc. to List on NYSE MKT
    Tuesday May 13, 2014
    Common Shares to Begin Trading on Friday May 16, 2014
    Symbol Remains "PVCT"

    KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), announced today that its shares of common stock have been approved for listing on the NYSE MKT. Shares will begin trading on the NYSE MKT on Friday May 16, 2014. The company's ticker symbol will remain "PVCT" but it will withdraw its shares from quotation on the OTCQB concurrent with listing its shares on the NYSE MKT.

    Dr. Craig Dees, PhD, CEO of Provectus said, "Listing on the NYSE MKT is a huge milestone for Provectus Biopharmaceuticals, and I take a great deal of personal satisfaction from this news. I believe that this will enhance our shareholder value as well as broaden our shareholder base and heighten our corporate profile in the capital markets."

    NYSE MKT is a fully integrated trading venue within the NYSE Euronext community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE Euronext community.

    "We welcome Provectus to the NYSE community and look forward to a strong partnership with the Company and its shareholders," said Scott Cutler, Executive Vice President and Head of Global Listings at NYSE Euronext. "Provectus will join other pharmaceutical companies that benefit from NYSE's trusted and reliable platform to raise capital."

    The complete press release is available at www.pvct.com/pressrelease.html?article=20140513 on the Provectus website.

    Disclosure: I am long PVCT.

    Stocks: PVCT
Back To Alan Robert Ross' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • Dennis R. Mahon
    , contributor
    Comments (444) | Send Message
     
    Yes Alan, this should be very good! I am most anxious to see PV-10 become available to ALL patients who want it, and ALL doctors who wish to administer it. Every month that passes without FDA approval is costing many melanoma patients their lives. Up-listing should bring more attention to PVCT the company and PV-10 the cancer killer.
    14 May 2014, 08:28 AM Reply Like
  • Alan Robert Ross
    , contributor
    Comments (450) | Send Message
     
    Author’s reply » Wait until you see the liver data and wait until the Market understands the huge size of that Market. The lymphatic system, as the major drainage in the system get the most mets. The liver because of its straining function is number 2 in the met parade.

     

    While treating melanoma in itself will be a >$1 Billion indication, helping liver cancer patients will be MANY times that. I've done the projections and it is huge.

     

    Look for a BTD application for liver cancer this year.
    14 May 2014, 09:20 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.